bone marrow cancer

Vidaza prolongs survival in patients with myelodysplastic syndromes

harminka — Thu, 11 Dec 2008 01:08:30 -0600

Results Presented at the 50th Annual Meeting of the American Society of Hematology Meeting

Continued treatment with vidaza can benefit MDS patients

harminka — Thu, 11 Dec 2008 01:01:56 -0600

The Myelodysplastic Syndromes (MDS) Foundation announced today that a new analysis of the AZA-001 phase III clinical trial demonstrates that continued treatment with VIDAZA (azacitidine) can improve response rates for higher-risk MDS patients.

Promising new drug blocks mutation in bone marrow cancers

harminka — Tue, 09 Dec 2008 14:24:44 -0600

Oregon Health & Science University Knight Cancer Institute researchers have found that an experimental drug successfully blocks an enzyme that causes some bone marrow cancers.

Race a factor in receiving transplant treatment for bone marrow cancer

harminka — Tue, 09 Dec 2008 06:53:52 -0600

A new study by researchers at The Medical College of Wisconsin Cancer Center Milwaukee, has found that African Americans and whites have identical survival rates after undergoing autologous (self donor) bone marrow transplant treatment for a common cancer of the bone marrow (multiple myeloma).

Study leads to protein linked to bone marrow failure in humans

harminka — Mon, 21 Jul 2008 07:50:53 -0500

The study of dark-skinned mice has led to a surprising finding about a common protein involved in tumor suppression, report researchers at the Stanford University School of Medicine. The results may lead to new treatments for bone marrow failure in humans.

Oral drug sets new survival standard for bone marrow cancer

harminka — Fri, 23 Nov 2007 11:24:19 -0600

Researchers from the Abramson Cancer Center of the University of Pennsylvania announced today that findings from two large, international clinical trials show unprecedented survival for patients with multiple myeloma, a cancer that occurs in the blood-making cells of bone marrow.

New Survival Standard for Bone Marrow Cancer

harminka — Thu, 22 Nov 2007 07:51:33 -0600

Findings from two large, international clinical trials show “unprecedented” survival for patients with multiple myeloma, a blood cancer that occurs in the blood-making cells of bone marrow. The findings demonstrate that with Revlimid®, an oral cancer drug, all measures of myeloma showed significant improvement in patients where previous treatments had failed.

Drug combination slows progression of treatment resistant bone marrow cancer

harminka — Tue, 12 Dec 2006 11:13:37 -0600

Drug combination proves effective against myeloma in Phase I trial

harminka — Mon, 11 Dec 2006 13:28:35 -0600